President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

President Trump signed an April 2026 executive order dedicating $50 million in federal funding toward ibogaine research for opioid addiction and PTSD.

From the articleUS advances first government-funded trials of psychedelic drug ibogaine | ReutersAlso in Pharmalittle: We're reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more